#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
“The adolescent brain doesn’t finish developing until the mid-20s, particularly the prefrontal cortex responsible for judgment and impulse control, which means regular cannabis use during these years carries real risks for cognitive function and motivation that we cannot simply dismiss as growing pains.”
💭 While this video headline addresses an important public health topic, the minimal engagement and lack of accessible summary details limit its utility for clinical decision-making. Adolescent cannabis use remains a legitimate concern given emerging evidence of potential impacts on neurodevelopment, academic performance, and mental health outcomes, though longitudinal research continues to evolve and causality remains incompletely understood. Clinicians should be aware that teen cannabis use patterns, potency, and frequency vary considerably across populations, and that many adolescents may not voluntarily disclose use without intentional, non-judgmental screening. Rather than relying on brief media segments for guidance, practitioners are better served consulting peer-reviewed literature and professional society recommendations when counseling teens and families about cannabis risks. In practice, incorporating routine, evidence-based substance use screening into adolescent visits and providing developmentally appropriate education about potential harms remains a straightforward way to address this issue.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: